Know what protections and rights you have as a study participant.
This right is absolute. You are never locked into a clinical trial. You can stop at any time, for any reason. You do not need permission. You do not need a medical excuse. You can say "I am done" and walk away. This protection is in federal rules. The Common Rule at 45 CFR 46.116 covers federally funded research, and FDA rules at 21 CFR 50.25 cover trials of FDA-regulated drugs and devices, including industry-sponsored trials.
Your medical care continues after withdrawal. If you were receiving standard medical treatment before the trial, you can go back to that. Federal rules say you can leave at any time without penalty or loss of benefits you are otherwise entitled to.
Some trials have safety-related taper schedules for withdrawal, especially for drugs that should not be stopped abruptly. The trial team will discuss this with you when you withdraw, but the team cannot force you to continue. You can request immediate discontinuation, accept a tapered withdrawal, or decline both. The decision is yours.
Before you enroll, the research team must explain the trial to you in language you can understand. They must describe the risks, the benefits, your rights, what the protocol requires, how data will be used, and what alternatives exist outside the trial. They provide written consent forms. You have the right to take time to read them, ask questions, take them home, and think about your decision before signing.
Signing consent means you understand what you are agreeing to. If you do not understand something, the team must explain it again. The consent form is not a gotcha. It is your protected right to fully understand what you are agreeing to before participating in research.
You can withdraw your consent at any time after signing. The signature does not lock you in. Your right to withdraw is restated in the consent form itself, and the trial team is required to honor that withdrawal without retaliation.
The 2018 revisions to the Common Rule strengthened informed consent requirements. Consent forms must now include a concise summary of the key information at the very beginning, written so a reasonable person could decide whether to participate. This summary rule applies to research covered by the Common Rule, which is mostly federally funded studies. If any consent form is hard to understand, ask the team to explain it, and contact the IRB if you still have concerns.
You have the right to be informed of any new findings during a clinical trial that might affect your willingness to continue participating. Federal rules require the consent form to promise this when it is relevant to the study, under 45 CFR 46.116(c)(5) and 21 CFR 50.25(b)(5). New findings can include safety signals from other participants, updated risk estimates, changes to the protocol, or information about a competing therapy that has become available.
When new safety information emerges, the IRB reviews whether the consent form needs to be revised and whether existing participants need to be reconsented. Reconsent is the formal process where the trial team re-explains the trial with the new information and asks you to sign an updated consent form. You can decline reconsent and withdraw, with no consequences for your medical care.
You can ask whether you will receive your own results. U.S. rules do not require trials to share them, but for federally funded studies the consent form may say whether and how individual results will be shared. Most trials of FDA-regulated drugs and devices, except Phase 1 drug trials and small device feasibility studies, must post summary results to ClinicalTrials.gov within 1 year after the primary completion date, which is when data collection for the main outcome ends. Some trials can get a delay. This is a public record that anyone can search.
Every legitimate clinical trial in the United States is reviewed and approved by an Institutional Review Board (IRB) before it starts. An IRB is a committee of at least 5 people with different backgrounds that reviews a trial to make sure it is ethical and that its risks are reasonable. It must include at least 1 scientist, at least 1 member whose main concerns are not scientific, and at least 1 member who is not affiliated with the institution. They review the informed consent forms, the protocol, and the qualifications of the research team. They ensure that the risks are justified by the potential benefits.
IRBs also monitor the trial while it is running. If problems come up, the IRB can require protocol changes, suspend enrollment, or stop the trial entirely. For FDA-regulated trials, the IRB must re-review the study at least once a year, and more often if the risk is higher. Under the 2018 Common Rule, some lower-risk federally funded studies no longer need yearly review.
You can contact the IRB directly if you have concerns about how a trial is being conducted. The consent form must tell you whom to contact with questions about your rights as a research participant. If the IRB is not listed, ask the study team for its contact information. If you do not feel comfortable raising a concern with the trial team, the IRB is the independent body that exists to receive participant complaints.
IRBs in the United States are regulated by the FDA and the Office for Human Research Protections (OHRP). Most academic medical centers have their own IRB, while many trial sponsors use a central commercial IRB (such as Advarra or WCG) to coordinate review across multiple sites. Both types must follow the same federal regulations.
Many trials, especially large ones and those testing riskier treatments, have a Data Safety Monitoring Board, or DSMB, also called a Data Monitoring Committee. NIH requires one for its multi-site trials of treatments that carry potential risk, and FDA guidance helps sponsors decide when other trials need one. This is an independent group of clinicians and statisticians who review accumulating trial data on a pre-specified schedule. The DSMB has access to unblinded outcome data that the front-line trial team cannot see during the trial.
The DSMB has three primary actions available. They can recommend stopping the trial early for efficacy if the active drug is working so well that continuing the comparator arm would be unethical. They can recommend stopping for safety if the drug is causing unexpected harm. They can recommend protocol modifications, such as adjusting the dose, changing inclusion criteria, or adding new safety assessments.
You will not interact with the DSMB directly, and the DSMB does not interact with individual participants. Their role is population-level oversight, designed to protect future enrollees and to catch trends that no individual trial team would see. Knowing a DSMB is monitoring your trial is one of the strongest assurances of independent safety oversight available in clinical research.
The informed consent form must disclose what compensation, if any, is available if you are injured by participating in a trial. Federal regulations do not require sponsors to provide compensation for injury, and policies vary from sponsor to sponsor and site to site.
For studies with more than minimal risk, the consent form must say whether compensation and medical treatment are available if you are injured, what they consist of, or where to get more information. It may not mention lost wages or long-term disability, so ask about those directly. If the consent form is silent or vague on this point, ask the coordinator before signing. Get the answer in writing.
If you experience a serious adverse event during a trial, document it in writing, request copies of all medical records, and contact the IRB if you feel the trial team is not being responsive. You can also report concerns to FDA MedWatch or to OHRP.
When your health information is held by a hospital, clinic or other health care provider covered by HIPAA, the HIPAA Privacy Rule controls how it can be used for research. Most clinical trials ask you to sign a HIPAA authorization, and an IRB or privacy board can approve some research uses without one. The authorization can be part of the consent form or a separate form. You can revoke it at any time in writing, but information already used or shared in reliance on it cannot be pulled back.
Your identifiable records can still be inspected by the FDA, and the consent form must tell you this. If results are published in medical journals, your name and identifying information are not included. Aggregate results posted to ClinicalTrials.gov also exclude personal identifiers. Research funded by NIH has been automatically covered by a Certificate of Confidentiality since 2017, and some other studies can apply for one. A Certificate of Confidentiality gives extra legal protection against being forced to disclose identifiable research information.
Ask the coordinator about data use before enrolling. How long will they keep your data? Who can access it? What happens to your data if you withdraw? In FDA-regulated trials, data collected before you leave stays part of the study and cannot be removed, though you can say no to further data collection. The HIPAA authorization form should specify the answer.
Federal regulations provide additional protections for participants who are considered vulnerable due to limited capacity to give voluntary informed consent. Subpart B of 45 CFR 46 covers pregnant women, fetuses, and neonates. Subpart C covers prisoners. Subpart D covers children. Each subpart adds specific consent and ethics requirements beyond the general Common Rule.
For children, parental permission is required, and children who are capable of it must also agree, which is called assent. The IRB decides who is capable based on the children's age, maturity and psychological state. The IRB reviews whether the trial offers direct benefit to the child and how risks compare to those a child would face in everyday life. If a pediatric study cannot be approved under the usual risk categories, it can go forward only after review by an expert panel and approval at the federal level, under 45 CFR 46.407 for HHS-funded research or 21 CFR 50.54 for FDA-regulated trials.
For adults who cannot make their own decision, such as people with severe cognitive impairment, a Legally Authorized Representative, or LAR, can consent on their behalf. State laws govern who qualifies as an LAR.
Trials that enroll prisoners, pregnant women in research not directly benefiting them, or other specifically vulnerable groups must include the protections detailed in the relevant subpart of 45 CFR 46. The IRB reviews these added protections and can require sponsor modifications before approval.
If you have concerns about how a trial is being conducted, you have multiple channels for raising them. Each channel addresses a different type of concern, and you can use more than one if appropriate.
The first contact for most concerns is the trial site IRB. Check your consent form for the contact listed for questions about your rights as a participant, and ask the study team for the IRB's contact information if it is not there. The IRB can investigate concerns about consent, conduct, or unexpected risks at the site level.
For concerns about a specific drug or device safety issue, FDA MedWatch is the federal mechanism for reporting adverse events. Reports can be filed online by patients, family members, or providers. If the problem happens during a trial, also tell the study team, because the sponsor must report serious and unexpected safety problems to the FDA.
For concerns about how human subjects research is conducted at a federally funded site, the Office for Human Research Protections (OHRP) accepts complaints under 45 CFR 46. OHRP can investigate institutions and require corrective action.
For concerns about discrimination, financial exploitation, or other patterns of misconduct, your state attorney general office, your state medical board, or a patient advocacy organization in your disease area can be appropriate next steps. Document everything in writing, keep copies of all correspondence, and seek legal advice if you believe you have been seriously harmed.
Clinical trial participants have the right to informed consent, the right to withdraw at any time without penalty, the right to be told about new information that could affect their participation, the right to privacy and HIPAA protection of their health data, the right to know about Institutional Review Board oversight of the trial, and the right to file complaints if they believe the trial is being conducted improperly. These rights are protected under federal regulations, including 45 CFR 46 for federally funded research and 21 CFR 50 and 56 for FDA-regulated trials.
Yes, you can withdraw from a clinical trial at any time, for any reason, without losing access to standard medical care. This right is required by federal regulations at 45 CFR 46.116 and 21 CFR 50.25. The informed consent form must explicitly state your right to withdraw. Some trials use a tapered withdrawal schedule for drugs that should not be stopped abruptly, but you cannot be forced to continue if you decide to leave.
Informed consent in a clinical trial is the process by which a potential participant learns the key facts of a study (purpose, procedures, risks, benefits, alternatives, costs, and rights) and decides whether to participate. The consent must be given freely, in a language the participant understands, and after they have had time to ask questions and consider their options. Federal regulations require informed consent for the research they cover, with limited exceptions, and list the required elements in 45 CFR 46.116 and 21 CFR 50.25.
An Institutional Review Board (IRB) is an independent committee that reviews and oversees clinical trials to protect human research subjects. The IRB reviews the protocol, the informed consent form, and the qualifications of the research team before approving a trial. The IRB also monitors the trial during conduct and can require changes, suspend enrollment, or stop the trial if problems arise. Every U.S. clinical trial requires IRB approval before it can begin.
A Data Safety Monitoring Board (DSMB), also called a Data Monitoring Committee, is an independent group of clinicians and statisticians who review accumulating clinical trial data while the trial is running. The DSMB has access to unblinded outcome data that the trial team cannot see during the trial. They can recommend stopping the trial early for efficacy, stopping for safety, or modifying the protocol. NIH requires DSMBs for its multi-site trials of treatments that carry potential risk, and FDA guidance helps sponsors decide when other trials need one.
Yes, your health information in a clinical trial is protected under HIPAA and additional research privacy regulations. Hospitals and clinics covered by HIPAA generally need your written authorization to use your health information for a clinical trial, although an IRB or privacy board can approve some uses without it. Published results do not include your name. NIH-funded studies are automatically covered by a Certificate of Confidentiality, which gives extra legal protection against forced disclosure of identifiable research information.
If you are injured in a clinical trial, the informed consent form must explain what compensation is available. Federal law does not require sponsors to provide compensation, and what is covered varies by sponsor and site. Coverage for medical care, lost wages, long-term disability, or pain and suffering is not guaranteed, so read this part of the consent form closely. Ask the coordinator before signing, and document any adverse event in writing if one occurs.
To file a complaint about a clinical trial, contact the trial site Institutional Review Board first, and ask the study team for the IRB's contact information if it is not on your consent form. For drug or device safety concerns, file a report with FDA MedWatch. For concerns about how human subjects research is conducted at a federally funded institution, contact the Office for Human Research Protections (OHRP). Document everything in writing and keep copies of all correspondence.
Children in clinical trials are protected under Subpart D of 45 CFR 46, which adds requirements beyond the general Common Rule. Parental permission is required, and children who are capable of it must also agree, which is called assent. The IRB decides who is capable based on age, maturity and psychological state, and reviews the balance of risks and direct benefit to the child. Pediatric studies that an IRB cannot approve under the usual risk categories need additional federal review under 45 CFR 46.407 or 21 CFR 50.54, and the FDA Pediatric Research Equity Act requires pediatric assessments for many new drugs.
Pick it below. One email when a new trial opens, a trial changes or the FDA acts on a treatment. Never a newsletter.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news. Turn any of these off from the link in every email.